Nevro (NYSE:NVRO) updated its second quarter 2021 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of – for the period. The company issued revenue guidance of $104 million-$106 million, compared to the consensus revenue estimate of $101.14 million.
Several research firms have recently issued reports on NVRO. Piper Sandler began coverage on Nevro in a research note on Tuesday, February 2nd. They set an overweight rating and a $190.00 price target for the company. SVB Leerink restated a buy rating on shares of Nevro in a research note on Thursday, March 4th. Morgan Stanley upped their price target on Nevro from $192.00 to $199.00 and gave the company an overweight rating in a report on Thursday, March 4th. Finally, Canaccord Genuity increased their price target on Nevro from $217.00 to $225.00 and gave the stock a buy rating in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Nevro presently has an average rating of Buy and an average price target of $188.83.
Nevro stock traded down $3.84 during midday trading on Wednesday, reaching $147.15. 2,435 shares of the company’s stock were exchanged, compared to its average volume of 469,839. Nevro has a 52 week low of $111.87 and a 52 week high of $188.14. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.75 and a current ratio of 3.10. The firm has a market cap of $5.12 billion, a price-to-earnings ratio of -55.19 and a beta of 1.02. The stock’s 50-day simple moving average is $152.30 and its 200 day simple moving average is $163.30.
In related news, insider Niamh Louise Pellegrini sold 750 shares of the business’s stock in a transaction on Wednesday, March 10th. The shares were sold at an average price of $148.08, for a total value of $111,060.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 7.60% of the stock is owned by insiders.
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems.
See Also: What is a portfolio manager?
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.